Earth Science Tech (OTCMKTS:ETST) vs. Pyxis Oncology (NASDAQ:PYXS) Financial Comparison

Pyxis Oncology (NASDAQ:PYXS) and Earth Science Tech (OTCMKTS:ETST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Analyst Ratings

This is a breakdown of current ratings for Pyxis Oncology and Earth Science Tech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	0	0	8	0	3.00
Earth Science Tech	0	0	0	0	N/A

Pyxis Oncology currently has a consensus price target of $9.00, indicating a potential upside of 138.10%. Given Pyxis Oncology’s higher probable upside, equities analysts clearly believe Pyxis Oncology is more favorable than Earth Science Tech.

Earnings and Valuation

This table compares Pyxis Oncology and Earth Science Tech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	N/A	N/A	-$73.79 million	($1.36)	-2.78
Earth Science Tech	$11.95 million	4.14	$810,000.00	N/A	N/A

Earth Science Tech has higher revenue and earnings than Pyxis Oncology.

Institutional & Insider Ownership

39.1% of Pyxis Oncology shares are owned by institutional investors. 9.3% of Pyxis Oncology shares are owned by insiders. Comparatively, 24.9% of Earth Science Tech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Pyxis Oncology and Earth Science Tech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-38.34%	-30.01%
Earth Science Tech	6.67%	23.85%	13.57%

Risk & Volatility

Pyxis Oncology has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Summary

Earth Science Tech beats Pyxis Oncology on 7 of the 10 factors compared between the two stocks.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

About Earth Science Tech

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.